GURUFOCUS.COM » STOCK LIST » USA » NAS » Atara Biotherapeutics Inc (NAS:ATRA) » Definitions » Interest Coverage
Switch to:

Atara Biotherapeutics Interest Coverage

: N/A (As of Jun. 2022)
View and export this data going back to 2014. Start your Free Trial

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Atara Biotherapeutics's Operating Income for the three months ended in Jun. 2022 was $-32.13 Mil. Atara Biotherapeutics's Interest Expense for the three months ended in Jun. 2022 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Atara Biotherapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Atara Biotherapeutics's Interest Coverage or its related term are showing as below:


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Atara Biotherapeutics Interest Coverage Historical Data

The historical data trend for Atara Biotherapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Interest Coverage
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt N/A N/A N/A

Atara Biotherapeutics Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Interest Coverage Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison

For the Biotechnology subindustry, Atara Biotherapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Atara Biotherapeutics Interest Coverage Distribution

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Interest Coverage falls into.



Atara Biotherapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt.


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Atara Biotherapeutics's Interest Coverage for the fiscal year that ended in Dec. 2021 is calculated as

Here, for the fiscal year that ended in Dec. 2021, Atara Biotherapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-340.46 Mil. And its Long-Term Debt & Capital Lease Obligation was $25.52 Mil.

GuruFocus does not calculate Atara Biotherapeutics's interest coverage with the available data.

Atara Biotherapeutics's Interest Coverage for the quarter that ended in Jun. 2022 is calculated as

Here, for the three months ended in Jun. 2022, Atara Biotherapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-32.13 Mil. And its Long-Term Debt & Capital Lease Obligation was $64.00 Mil.

GuruFocus does not calculate Atara Biotherapeutics's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Atara Biotherapeutics  (NAS:ATRA) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Atara Biotherapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Atara Biotherapeutics Business Description

Atara Biotherapeutics logo
Traded in Other Exchanges
Address
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and CAR T Programs.
Executives
Yarema Kristin officer: Chief Commercial Officer C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD., SUITE 900 SOUTH SAN FRANCISCO CA 94080
Murugan Amar officer: SVP, GC & Secretary C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD,SUITE 900 SOUTH SAN FRANCISCO CA 94080
Dupont Jakob officer: EVP, Head of R&D C/O ONCOMED PHARMACEUTICALS, INC. 800 CHESAPEAKE DRIVE REDWOOD CITY CA 94063
Touchon Pascal director, officer: President and CEO C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Koppikar Utpal officer: Chief Financial Officer C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD, SUITE 900 SOUTH SAN FRANCISCO CA 94080
Mallik Ameet director C/O RAFAEL HOLDINGS, INC. 520 BROAD ST NEWARK NJ 07102
Renaud Ronald C Jr director C/O IDENIX PHARMACEUTICALS, INC. 60 HAMPSHIRE STREET CAMBRIDGE MA 02109
Seidenberg Beth C director
Heiden William K director C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451
Dobmeier Eric director C/O SAETTLE GENETICS INC 21823 30TH DRIVE SE BOTHELL WA 98021
Roncarolo Maria Grazia director C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080
Gallagher Carol Giltner director C/O ATARA BIOTHERAPEUTICS, INC. 3260 BAYSHORE BOULEVARD BRISBANE CA 94005
Fust Matthew K director C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949
Baynes Roy D. director C/O RETROPHIN, INC. 12255 EL CAMINO REAL, SUITE 250 SAN DIEGO CA 92130
Berger Dietmar officer: Global Head of R&D C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080

Atara Biotherapeutics Headlines

From GuruFocus

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)